Catalog number: 421 - 60535
Product Category: Business & Industrial > Science & Laboratory
Size: 2 vials
60538
Recombinant Jurkat cell line constitutively expressing a full length human TIGIT (T_x000D_cell Immunoreceptor with Immunoglobulin and ITIM domain; VSTM3), and a firefly luciferase_x000D_gene under the control of nuclear factor of activator T cells (NFAT) response element. Both_x000D_TIGIT and NFAT constructs have been stably integrated into Jurkat cells. TIGIT expression has_x000D_been confirmed by Western Blot, and TIGIT-specific NFAT response has been validated using a_x000D_TIGIT ligand, CD155 (PVR).
60621
The NFAT Reporter - Jurkat Cell Line contains a firefly luciferase gene under the control of the_x000D_NFAT response element stably integrated into Jurkat cells. This cell line has been validated for_x000D_response to thapsigargin, ionomycin, and phorbol 12-myristate 13-acetate (PMA). It is useful as_x000D_a control cell line for other NFAT reporter cell lines expressing various immune checkpoint_x000D_receptors.
79668
Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of a chimeric receptor consisting human ICOS (also known as inducible T-cell costimulator or CD278, Genbank Accession #NM_012092) and the cytoplasmic domain of human CD3 zeta._x000D_
79853
Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells.<br /><br />Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3ζ signaling domain.<br />
78322
Recombinant Jurkat cell line expressing firefly luciferase under the control of an IL-2-responsive promoter, and with constitutive expression of human KIR3DL3 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 3; GenBank accession #BC143802.1 corresponding to KIR3DL3*00402 allele). HHLA2 (B7-H7) mediates an immune-stimulatory signal via TMIGD2 (Transmembrane and immunoglobulin domain containing 2; CD28H) in naïve T cells while it delivers an immune-inhibitory signal through KIR3DL3 in activated T cells and Natural Killer (NK) cells.